COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment

COVID-19 disease increases interleukin (IL)-1β release. Anti-IL-1-treatment is effective in IL-1-mediated autoinflammatory diseases (AID). This case series presents COVID-19 in patients with IL-1-mediated and unclassified AID with immunosuppressive therapy (IT). Patient 1 is a 34-year-old woman with...

Descripción completa

Detalles Bibliográficos
Autores principales: Welzel, Tatjana, Samba, Samuel Dembi, Klein, Reinhild, van den Anker, Johannes N., Kuemmerle-Deschner, Jasmin B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915607/
https://www.ncbi.nlm.nih.gov/pubmed/33562758
http://dx.doi.org/10.3390/jcm10040605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915607/
https://www.ncbi.nlm.nih.gov/pubmed/33562758
http://dx.doi.org/10.3390/jcm10040605

Ejemplares similares